Personalized RNA vaccine induces T cell responses in melanoma

Mainz, July 5th 2017 – Today, TRON and BioNTech AG announced the publication of Phase I clinical trial results in the renowned journal Nature.

In this worldwide first-in-human clinical study, an RNA-vaccine based on patient-specific mutations (IVAC® MUTANOME) was tested. The study demonstrates that a personalized RNA-based vaccine encoding for multiple individual mutations specifically activates the immune system and exerts anti-tumoral reactivity.

Please find further details regarding the publication in the official press release. The advanced online publication of the article can be accessed on Nature’s webpage.